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Conclusions. A simple score (CRD-45 TB-score) based on 4 clinical variables was highly 
predictive for the in-house mortality in patients with tuberculosis from this cohort. Generability 
of this score to predict in-house morbidity of patients with tuberculosis should be prospectively 
evaluated in a larger multicenter cohort. 
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Introduction. For the treatment of MDR and XDR tuberculosis, it is important to select the most 
suitable drug regimen. The resistance testing procedure should be as fast and accurate as 
possible. Within the framework of personalized medicine, the most suitable therapy approach for 
the individual patient should be found. With the faster available information from a new form of 
susceptibility testing, the best regimen could be created in a shorter period of time and the 
appropriate therapy for the patient could be initiated. 
Aim of the study. With our study we want to compare the genotypic drug resistance testing with 
phenotypic drug resistance testing. It will demonstrate to what extent the measured resistance 
results overlap and where there may be differences. 
Materials and methods. We compared the utility of genotypic DST assays with phenotypic DST 
(pDST) using Bactec 960 MGIT or Löwenstein-Jensen to construct M/XDR-TB treatment 
regimens for a cohort of 25 consecutive M/XDR-TB patients and 15 possible anti-TB drugs. 
Genotypic DST results from Cepheid GeneXpert MTB/RIF (Xpert) and line probe assays (LPAs; 
Hain GenoType MTBDRplus 2.0 and MTBDRsl 2.0) and whole-genome sequencing (WGS) 
were translated into individual algorithm-derived treatment regimens for each patient. We further 
analyzed if discrepancies between the various methods were due to flaws in the genotypic or 
phenotypic test using MIC results. 
Results. Compared with pDST, the average agreement in the number of drugs prescribed in 
genotypic regimens ranged from just 49% (95% confidence interval [CI], 39 to 59%) for Xpert 
and 63% (95% CI, 56 to 70%) for LPAs to 93% (95% CI, 88 to 98%) for WGS. Only the WGS 
regimens did not contain any drugs to which pDST showed resistance. Importantly, MIC testing 
revealed that pDST likely underestimated the true rate of resistance for key drugs (rifampin, 
levofloxacin, moxifloxacin, and kanamycin) because critical concentrations (CCs) were too high. 
Conclusions. With the analysis of the genome, even in M/XDR strains with complex resistance 
patterns it is possible to characterize these resistances. The procedure is fast and the results are 
very similar to those of phenotypic testing. Only for some drugs, the susceptibility test has to be 
carried out phenotypically in order to compile the final regimes. 
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